Sowmy Thuppal
Springfield, Illinois, 62704, United States
Location status: Recruiting
Location contact
CONTACT
NCT Number: NCT06084078
The role of this observational study is to access the feasibility of providing lung cancer screening using a designated nurse navigator through lung cancer screening clinic. Eligible participants will be identified using medical records, eligibility will be confirmed through phone call, screening visits will be scheduled as in-person visit or telehealth visit. Computed tomography screening will be performed at an approved center closer to the individuals place of living and results will be discussed during follow-up in-person visit or telehealth visit.
Interested in participating?
Request Info50 year–80 year
All sexes
Observational
Springfield, Illinois, 62704, United States
Location status: Recruiting
CONTACT
The long-term goal is to establish healthcare practices to increase adherence to lung cancer screening among high-risk individuals. The overall objective in this application is to establish a lung cancer screening initiative to proactively identify and screen eligible patients for LDCT using a designated nurse practitioner (NP) along with telehealth. The central hypothesis is that use of a designated NP along with telehealth will increase lung cancer screening via LDCT among high-risk, racial/ethnic minority, and rural/sub-urban patients. The rationale for this proposal is use of a NP and telehealth will help overcome the barriers physicians face in identifying eligible patients for LDCT including collecting additional information to determine eligibility, discussing the pros and cons of LDCT, providing smoking cessation/abstinence counseling, making shared decisions, and documenting this information in the patients' charts.
In this prospective cohort study the nurse practitioner (NP) will proactively identify eligible individuals for LDCT using EMRs that are shared across the Department of Family and Community Medicine at SIU. These patients will be contacted and those agreeing to undergo screening will be given a referral to a nearby LDCT center. The NP will follow-up with the patients with the results of the LDCT and will refer them for further management to their primary care physician. If the results are negative for nodules then they will be followed up on a yearly basis until the participants are older than 80 years or have other life-threatening health issues.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Through study completion, an average of 1 year
Percentage of individuals screened (completed CT imaging) with and without telehealth
Time frame: Through study completion, an average of 1 year
Percentage of individuals diagnosed with lung cancer at an early stage of the disease
Time frame: Through study completion, an average of 1 year
Number of days from diagnosis to treatment initiation will be calculated for each patient diagnosed with lung cancer
Time frame: Through study completion, an average of 1 year
Percentage of of individuals undergoing yearly screening with and without telehealth
Time frame: Through study completion, an average of 1 year
Overall cost from pre-screening to screening and follow-up with and without telehealth
Contact information is provided by the study sponsor or research team.
Southern Illinois University
Other
Patient Identification, Prescreening and LDCT Screening for Lung Cancer With Telehealth
Acronym: LDCT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06540196
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hamilton, Ontario, Canada
View Trial DetailsNCT06410300
Lung Cancer, Lung Diseases
Columbia, Missouri, United States
View Trial DetailsNCT01441089
Adnexal Diseases, Breast Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT00034216
Breast Cancer, Breast Diseases
Bethesda, Maryland, United States
View Trial Details